SCHEMBL2237567

SCHEMBL2237567

Cc1cccc(-c2nc(NCCc3cccc(O)c3)cc(-c3cccnc3)n2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.51
PIK3CB P42338 2/20 0.51
PIK3CG P48736 2/20 0.51
PTGDR Q13258 4/20 0.49
CYP2A6 P11509 1/20 0.48
CYP3A4 P08684 3/20 0.42
CYP2C9 P11712 1/20 0.42
ROS1 P08922 3/20 0.42
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
HPGD P15428 2/20 0.41
CYP2C19 P33261 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240876 0.91 PTGDR (0.55) PIK3CAPIK3CBPIK3CGPTGDRCYP2A6
SCHEMBL2235666 0.82 PTGDR (0.48) PIK3CAPIK3CBPIK3CGPTGDRCYP2A6
SCHEMBL2237571 0.81 SPR (0.57) PTGDRCYP3A4CYP2C9ALDH1A1CYP1A2
SCHEMBL4773623 0.77 CYP3A4 (0.48) PIK3CAPIK3CBPIK3CGPTGDRCYP2A6
SCHEMBL2239418 0.77 CYP3A4 (0.52) PIK3CAPIK3CBPIK3CGCYP2A6CYP3A4
SCHEMBL2242475 0.77 PTGDR (0.54) PIK3CAPIK3CBPIK3CGPTGDRCYP2A6
SCHEMBL2240068 0.77 CDK4 (0.55) PTGDRCYP2A6CYP3A4CYP2C9ALDH1A1
SCHEMBL2240699 0.77 CYP3A4 (0.44) PIK3CAPTGDRCYP2A6CYP3A4CYP2C9
SCHEMBL2238098 0.76 PTGDR (0.53) PIK3CAPIK3CBPIK3CGPTGDRCYP2A6
SCHEMBL2238361 0.75 PTGDR (0.49) PTGDRCYP2A6CYP3A4CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP claimed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US claimed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US claimed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP claimed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO claimed
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK PIK3CA 222/4885PIK3CB 536/4885PIK3CG 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.